Atossa Therapeutics (ATOS) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Rodman & Renshaw | Initiated Coverage | Buy | $12.00 | Jul 7, 2026 |
| Ascendiant Capital | Maintained | Buy | $24.00 from $120.00 | Apr 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $7.00 | Mar 26, 2026 |
| Ascendiant Capital | Maintained | Buy | $8.00 from $7.75 | Dec 8, 2025 |
| Ascendiant Capital | Maintained | Buy | $7.75 from $7.50 | Sep 22, 2025 |
| Ascendiant Capital | Maintained | Buy | $7.50 from $7.25 | Jun 6, 2025 |
| Craig-Hallum | Initiated Coverage | Buy | $4.00 | Jun 5, 2025 |
| Ascendiant Capital | Maintained | Buy | $7.25 from $7.00 | Apr 21, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Mar 26, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Mar 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jan 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Dec 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | — | Dec 12, 2024 |
| Ascendiant Capital | Maintained | Buy | $7.00 from $6.50 | Dec 9, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $6.00 | Nov 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Nov 5, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Oct 31, 2024 |
| Ascendiant Capital | Maintained | Buy | $6.50 from $6.25 | Sep 11, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Aug 12, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Jun 28, 2024 |
Frequently asked questions
Is ATOS a buy, sell, or hold?
Analysts covering Atossa Therapeutics currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ATOS?
On Jul 7, 2026, Rodman & Renshaw initiated coverage of Atossa Therapeutics at Buy with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.